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ANALYSIS OF RISK FACTORS IN ADULTS TRANSPLANTED WITH UCB
FOR TREATMENT OF HEMATOLOGIC MALIGNANCY
Guillermo F. Sanz, Susana Cantero, Luis Larrea, Dolores Planelles,
Ignacio Lorenzo, Luis Benlloch, Leonor Senent, Pau Montesinos, Jose
Cervera, Guillermo Martin, Jesus Martinez, Isidro Jarque, Javier de la
Rubia, and Miguel A. Sanz Department of Hematology, Hospital Uni-
versitario La Fe, Valencia, Spain
Risk factors analyses are urgently required for determining which
variables should guide the selection of the best UCB unit for
transplantation in adults. This study evaluated prognostic factors of
outcome in 92 adults with hematologic malignancy undergoing
single-unit UCBT in a single institution. Conditioning consisted
of thiotepa, busulfan, cyclophosphamide or ﬂudarabine, and anti-
thymocyte globulin (ATG). Median age and weight were 31 yr and
71 kg. Degree of HLA was 6/6 in 5, 5/6 in 33, and 4/6 in 54 cases.
The median number of nucleated and CD34 cells infused was
2.1  10E7/kg and 1  10E5/kg respectively. The cumulative
incidence of myeloid engraftment, grade III-IV acute GVHD, and
non-relapse mortality (NRM) at 100 days was 90%, 18%, and 25%
respectively. The cumulative incidence of relapse and the proba-
bility of disease-free survival (DFS) at 3 years were 21% and 39%
(median follow-up, 26 months). Multivariate analyses showed that
the absolute number of CD34 cells in the UCB unit was the most
important predictor of myeloid and platelet engraftment. The use
of rabbit ATG was related to faster platelet engraftment and lower
incidence of acute GVHD. The development of grade II-IV acute
GVHD was associated with slower platelet engraftment and
greater NRM. Older patients had a greater NRM whereas condi-
tioning with thiotepa, ﬂudarabine, intravenous busulfan as a single
daily dose, and rabbit ATG and higher numbers of CD3 cells
infused were associated with a lower NRM. Relapse risk was lower
for patients with chronic myelogenous leukemia and those trans-
planted in early stage. The only variable independently associated
with DFS was the stage of the disease at transplant. The number of
nucleated cells and HLA mismatches did not impact any outcome.
These results show that the current criteria for selecting the best
unit for UCBT in adults need to be modiﬁed.
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DONOR-RECIPIENT HOST-VERSUS-GRAFT HUMAN LEUKOCYTE ANTI-
GEN MISMATCHES AND OUTCOME OF CORD BLOOD TRANSPLANTS
Marcos de Lima, Poliana A. Patah, Rima Saliba, Daniel Couriel,
Kawah Chan, Laura Worth, Sergio Giralt, Partow Kebriae, Issa
Khouri, Laurence Cooper, Marcelo Fernandez-Vina, Pedro Cano, Dem-
etrios Petropoulos, John McMannis, Chitra Hosing, Gabriela Rondon,
Krishna V. Komanduri, Richard E. Champlin and Elizabeth J. Shpall
Department of Stem Cell Transplantation and Cell Therapy, University
of Texas MD Anderson Cancer Center, Houston, TX, USA
The inﬂuence of HLA mismatches on outcomes of cord blood
transplants (CBT) is yet to be fully understood. We hypothesized
that donor-recipient mismatches in the host-versus-graft (HVG)
and graft-versus-host (GVH) direction impact engraftment, non-
relapse mortality (NRM) and survival after CBT, and addressed
the question studying CBT performed in our institution. We also
analyzed the possible contribution of HVG and GVH mismatches,
and graft-versus-graft mismatches in predicting which CB unit
would prevail after double CB transplants. We studied 91 patients.
Diagnoses were high-risk hematologic malignancies (n85; 93%)
or non-malignant disorders (n6; 7%). Conditioning was myeloa-
blative (n86; 95%), while patients not eligible for high-dose
therapy received reduced-intensity (n5; 5%) regimens. ATG was
part of the preparative regimen in 45 cases (49%). Graft-versus-
host disease (GVHD) prophylaxis was tacrolimus with (n83;
91%) or without methotrexate (n6; 6%), and cyclosporine and
MMF (n2; 2%). Grafts were single (n70; 77%) or double
(n21; 23%) CB units. Nine patients received ex-vivo expanded
grafts. For patients receiving a double CBT, the engrafted unit was
used as the reference for this analysis. HLA-A, B (intermediate
resolution) and DRB1 typing (high-resolution) was available for all
donor-recipient pairs. Median age was 18 years (range, 1-57); 46
(51%) were younger than 18 years old and 50 patients (55%) were
males. The patients were heavily pre-treated with 18 (20%) having
received prior autologous transplants. Disease status at CBT was
complete remission (CR; n43; 47%) and active disease (n48;
53%). Median number of infused total nucleated cells (TNC) was
3.45x10E7/kg (0.81-23.6). Numbers of mismatches in the HVG
direction were as follows: zero (n11), 1 (n37), 2 (n36), 3
(n6), and 4 (n1). Numbers of mismatches in the GVH direction
were as follows: zero (n8), 1 (n35), 2 (n41), and 3 (n7). 78
patients engrafted neutrophils (86%) at a median of 22 days (4-60).
65 patients engrafted platelets (71%) at a median of 42 days
(0-133). 13 patients (14%) failed to engraft. Grade II–IV and
III–IV acute GVHD rates were 49% and 8%, respectively, and
chronic GVHD incidence was 33%. 35 patients are alive with a
median follow-up of 25 months. 2-year actuarial survival is 21%.
100-day and 1-year NRM is 22% (14-32) and 37% (28-49). One-
year NRM was 21% (CI: 6-74) for patients that received grafts
without HVG HLA mismatches, while it was 33% (CI: 20-54) for
those with one mismatch, 47% (CI: 33-67) for those with two
mismatches, and 33% (CI: 11-100) for those with three mis-
matches (PNS). The proportion of patients that engrafted was
100% for the group without HVG mismatches, while it was 89%,
85% and 83%, respectively for patients with one, two or three
mismatches. The decreasing 2-year survival and worse NRM as-
sociated with increasing number of HVG mismatches was limited
to the group of patients younger than 18 years. There was no
difference in the proportion of patients in CR, or in the distribu-
tion of infused TNC/Kg across the HVG mismatch subgroups.
There was no correlation between mismatches in the GVH direc-
tion and NRM or 2-year survival. In addition, the number and
direction of HLA mismatches among CB units and recipient did
not predict which unit would prevail after double CB transplants.
We conclude that HVG mismatches may inﬂuence outcomes of
CBT.
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UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
(HSCT) IN CHILDREN WITH ACUTE LEUKEMIA: RISKS AND BENEFITS
OF UMBILICAL CORD BLOOD (UCB) VERSUS ALLELE-MATCHED BONE
MARROW (BM)
Mary Eapen, MD, MS Center for International Blood and Marrow
Transplant Research (CIBMTR), Medical College of Wisconsin, Mil-
waukee, WI
Though UCB has proven to be an acceptable alternative to BM
for transplantation, it is unknown how UCB mismatched at HLA
0-2 loci compares to HLA matched BM. Therefore, we compared
transplant results observed in 503 recipients of UCB with those in
116 recipients of allele-matched (at HLA A, B, C, DRB1) BM. Of
UCB recipients, 35 were matched at HLA A, B (antigen-level) and
DRB1 (allele-level), 201 were mismatched at 1-locus and 267 were
mismatched at 2-loci. Compared to recipients of allele matched
BM, UCB recipients were younger, non-Caucasian, more likely to
have advanced disease at HSCT, less likely to receive radiation and
somewhat more likely to receive cyclosporine. As previously ob-
served, probability of neutrophil recovery (500/ul) at day 42
depended on graft type, HLA disparity and cell dose: 97% with
BM; 85% with HLA matched UCB; 79% with 1-2 locus mis-
matched UCB/high cell dose (0.3  108/kg) and 64% 1-2 locus
mismatched UCB/low cell dose (0.3  108/kg). Compared to
allele-matched BM, risks of grade 2-4 graft-versus-host disease
(GVHD) was lower with HLA matched CB (RR 0.45, p0.04) and
similar after 1 or 2 loci HLA mismatched UCB. Risks of chronic
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GVHD were marginally lower after HLA matched or mismatched
UCB transplants than after allele-matched BM. Notably, leuke-
mia-free survival (LFS) rates at 5 years were comparable between
those receiving allele matched BM (38%) and 1 locus high cell dose
(41%), 1 locus low cell dose (37%) or 2 loci (33%) HLA mis-
matched UCB. The observed higher LFS rate (60%) after HLA
matched UCB transplant requires validation in a larger cohort.
These results in LFS are in part explained by differences in risks of
transplant related mortality (TRM) and relapse between patient
populations. Compared to allele-matched BM transplants, TRM
was similar in recipients of matched and 1-locus mismatched UCB
and higher in recipients of 2-loci mismatched UCB. Conversely,
relapse rates were lower in recipients of UCB transplants mis-
matched at 2-HLA loci. These results are the ﬁrst to support the
use of HLA matched or mismatched UCB grafts with an adequate
cell dose as a ﬁrst line transplant treatment regardless of the
availability of a HLA allele-matched BM donor in the setting of
acute leukemia in children aged 16 years.
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INFLUENCE OF HLA DISPARITY AND GRAFT LYMPHOCYTES ON ALLO-
GENEIC ENGRAFTMENT AND SURVIVAL AFTER UMBILICAL CORD
BLOOD TRANSPLANT IN ADULTS
Willem J. van Heeckeren1, Laura R. Fanning1, Howard J. Meyerson2,
Pingfu Fu3, Hillard M. Lazarus1, Brenda W. Cooper1, Stanton L.
Gerson1, William W. Tse1, Tamila L. Kindwall-Keller1, Jennifer
Jaroscak4, Marcie Finney1, Robert N. Fox5, Luis Solchaga5, Margaret
Forster1, Richard J. Creger1, and Mary J. Laughlin1,2 1Department of:
Medicine, 2Pathology, 3Epidemiology and Biostatistics, 4Pediatrics, 5Case
Comprehensive Cancer Center, Case Western Reserve University, Cleve-
land, OH
Graft nucleated cell and CD34 hematopoietic progenitor cell
dose are predictors of allogeneic engraftment and survival in um-
bilical cord blood (UCB) recipients. In this single institution pro-
spective phase II trial, ﬂow cytometric analyses of CD34 progen-
itor and lymphocyte populations in unmodiﬁed single unit HLA-
disparate UCB grafts infused into 31 consecutive adults (median
age 41 years, range 20-64) receiving myeloablative conditioning
were compared with clinical outcomes. Median infused UCB graft
nucleated cells and CD34 dose was 2.2  107/kg and 1.2 
105/kg respectively. Day to absolute neutrophil count  500/L
with full donor chimerism averaged 27 days (range 12-41). Uni-
variate analyses demonstrated that UCB graft infused cell doses of
CD34 (p0.015), CD3 (p0.024) and CD34HLADR
CD38 progenitors (p0.043) correlated with neutrophil engraft-
ment. High-resolution matching for HLA-Class II (DRB1) re-
sulted in improved event-free survival (EFS) (p0.02) and de-
creased risk for acute graft versus host disease (GVHD) (p0.004).
Early mortality (prior to post-transplant day 28) occurred in
three patients, while twenty-six patients achieved myeloid engraft-
ment. These results suggest that UCB graft matching at DRB1 is
an important risk factor for acute GVHD and survival, while
higher UCB graft cell doses of CD34, committed CD34 pro-
genitors and CD3 T-cells favorably inﬂuence UCB allogeneic
engraftment.
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DOUBLE UMBILICAL CORD BLOOD TRANSPLANTATION AFTER MY-
ELOABLATION
John E. Wagner, M.D. and Claudio Brunstein, M.D. Blood and Mar-
row Transplant Program, University of Minnesota, Minneapolis, MN
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Cryopreserved umbilical cord blood (UCB) has been investigated
as a potential strategy for augmenting the pool of acceptable
donors, reducing the risks of acute and chronic graft-versus-host
disease (GVHD) and improving survival. Cell dose, however, has
clearly been identiﬁed as a major limitation, often preventing the
consideration of UCB for adult recipients. Recipients of 2.5 
107 nucleated cells/kg have slow hematopoietic recovery and sig-
niﬁcantly lower incidence of engraftment. Therefore, we explored
the potential of infusing two partially HLA matched units to
augment cell dose in patients who did not have an UCB graft
containing2.5 107 nucleated cells/kg. The underlying hypoth-
esis is that the addition of the second unit will enhance engraftment
and speed of hematopoietic recovery. One-hundred and twenty-
two patients [median age 23.2 years (range: 2.9-45.8); median
weight 64 kg (range: 12.6-148.6)] with high-risk hematologic ma-
lignancy were transplanted with a partially HLA-matched UCB
graft (70% received two units) after a single myeloablative condi-
tioning consisting of ﬂudarabine 75 mg/m2, cyclophosphamide 60
mg/kg and total body irradiation 1320 cGy. All received cyclospor-
ine and mycophenolate mofetil posttransplant immunoprophylaxis.
Patients had AML (n51), ALL (n46), CML (n10), MDS
(n4) or NHL (n11). The median total infused dose was 4.4 
107 NC/kg (range 1.1-13.9). The incidence of neutrophil recovery
was 91% (95% CI, 86-96) at a median of 23 days with no difference
observed in recipients of one or two units. Only CD34 cell dose
predicted incidence and speed of recovery. After engraftment, one
unit predominated in 90% with no factor (nucleated cell dose,
CD34 cell dose, HLA-match, ABO, sex, or order of infusion)
predicting which unit would predominate long term. Incidence of
grades II-IV and III-IV acute graft-versus-host disease (GVHD)
was 55% (95% CI, 44-66) and 17% (95% CI, 9-25) at day 100 with
an increased incidence of grade II disease only in recipients of two
units. Incidences of transplant-related mortality and relapse was
25% (95% CI, 17-33) at 1 year and 22% (95% CI, 12-32) at 2
years, respectively. Probabilities of overall and event-free survival
are 59% (95% CI, 49-69) and 51% (95% CI, 40-62) at 2 years,
respectively. Notably, recipients of two units had a trend toward
reduced relapse and improved event-free survival. These data sug-
gest that 1) double unit UCBT is safe with one unit predominating
over time, 2) double unit UCBT may extend the application of
UCB to nearly all adults and adolescents, and 3) double UCBT
may be associated with lower relapse and higher survival in those
with acute leukemia in complete remission. A NIH-CTN spon-
sored, multi-institutional randomized trial comparing outcomes in
recipients of single versus double UCB transplantation is open for
accrual.
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EFFECT OF CD26 ON CORD BLOOD, AND OTHER MEANS TO ENHANCE
ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS
Hal E. Broxmeyer, Ph.D. Indiana University School of Medicine, Indi-
anapolis, Indiana
A major goal of our laboratory and the focus of this presentation
is to enhance the efﬁciency of cord blood transplantation through
a better understanding of the mechanisms regulating hematopoi-
esis, and hematopoietic stem (HSC) and progenitor cell functions.
We have found that inhibition of CD26/Dipeptidylpeptidase IV
(DPPIV) with small peptides, such as Diprotin A (Ile-Pro-Ile) or
Val-Pyr enhance the capacity of human cord blood CD34 cells
and mouse Sca1c-kitLin bone marrow cells to respond to the
chemotactic activity of stromal cell derived factor (SDF-1/
CXCL12) in vitro (Christopherson, et al. J. Immunol 169:7000-
7008, 2002) and they enhance donor mouse bone marrow HSC
homing and engraftment of lethally irradiated recipient mice in
both a competitive and a non-competitive assay (Christopherson,
et al. Science 30:1000-1003, 2004). Enhanced engrafting capability
of gene transduced mouse bone marrow cells into lethally irradi-
ated mice (Tian, et al. Gene Therapy 13:652-658, 2006) and mouse
bone marrow cells in utero into mice (Peranteau, et al. Blood
108:4268-4274, 2006) has been noted by others in the context of
Diprotin A inhibition of CD26/DPPIV on donor cells. We now
report that inhibition of CD26/DPPIV in human cord blood
CD34 cells enhances their engraftment of non obese diabetic
(NOD)/Severe Combined Immunodeﬁcient (SCID) mice (Camp-
bell, et al. Stem Cells and Development [SCD], 16:347-353, 2007).
Others have seen Diprotin A enhancement of CD34 cord blood
(Christopherson, et al. SCD 16:355-360, 2007) and G-CSF mobi-
lized adult peripheral blood CD34 (Kawai, et al. SCD 16:361-
370, 2007) cells respectively by pretreating donor CD34 cells, or
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